CABA vs. PHAT, PRME, RVNC, TKNO, ATXS, ORKA, GLUE, AURA, ETON, and CADL
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Phathom Pharmaceuticals (PHAT), Prime Medicine (PRME), Revance Therapeutics (RVNC), Alpha Teknova (TKNO), Astria Therapeutics (ATXS), Oruka Therapeutics (ORKA), Monte Rosa Therapeutics (GLUE), Aura Biosciences (AURA), Eton Pharmaceuticals (ETON), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.
Cabaletta Bio vs.
Phathom Pharmaceuticals (NASDAQ:PHAT) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 6 mentions for Phathom Pharmaceuticals and 3 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.95 beat Phathom Pharmaceuticals' score of 0.56 indicating that Cabaletta Bio is being referred to more favorably in the news media.
Phathom Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500.
Phathom Pharmaceuticals and Cabaletta Bio both received 91 outperform votes by MarketBeat users. However, 72.80% of users gave Phathom Pharmaceuticals an outperform vote while only 72.22% of users gave Cabaletta Bio an outperform vote.
Cabaletta Bio has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Phathom Pharmaceuticals currently has a consensus price target of $23.00, indicating a potential upside of 341.46%. Cabaletta Bio has a consensus price target of $22.71, indicating a potential upside of 1,260.14%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Phathom Pharmaceuticals.
Cabaletta Bio has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Cabaletta Bio's return on equity.
Summary
Cabaletta Bio beats Phathom Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
This page (NASDAQ:CABA) was last updated on 3/3/2025 by MarketBeat.com Staff
Free CABA Stock Alerts